Latest News
News
Psoriasis, psoriatic arthritis insurance coverage remains restrictive
A database review showed restrictive coverage of specialty medications for psoriatic disease beyond the label indications.
News
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depth
Patients with immune-mediated inflammatory diseases have weaker vaccine-induced immunity to COVID but are able to build a humoral immune response...
News
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.
News
Proactive infliximab monitoring found best for sustaining control of inflammatory diseases
Proactive therapeutic drug monitoring with maintenance infliximab proved more effective in sustaining disease control than did standard care in...
News
Better COVID-19 outcomes confirmed in TNF inhibitor users
A study of three international registries confirms that patients with immune-mediated inflammatory diseases who are taking a TNF inhibitor should...
News
Study of biologics’ impact on psoriasis-to-PsA transition contradicts previous findings
Differing patient selection criteria and other biases may be why results from a large EHR administrative database study contradict those from...
Latest News
European agency recommends two new adalimumab biosimilars
The Committee for Medicinal Products for Human Use gave a positive opinion for the approval of Hukyndra and Libmyris, each of which will have 15...
News
Medicare patients’ cost burden for specialty psoriasis, PsA drugs remains high
Coverage of and access to biologics for psoriasis and psoriatic arthritis are compromised by out-of-pocket payments and prior authorization...
Conference Coverage
Physicians question the future of TNF inhibitors for psoriasis, PsA
Two dermatologists and two rheumatologists debate the merits of using IL-17 and IL-23 inhibitors ahead of TNF inhibitors for the treatment of...
News
Cumulative exposure to high-potency topical steroid doses drives osteoporosis fractures
"A 3% increase in the relative risk of osteoporosis and MOF was observed per doubling of the TCS dose."